The global cell cycle analysis market is experiencing exponential growth. Valued at USD 22.51 billion in 2024, it rose to USD 24.99 billion in 2025 and is projected to reach USD 63.94 billion by 2034, expanding at a CAGR of 11.02% from 2025 to 2034. This surge is fueled by increasing applications in R&D, technological advancements, and AI integration that streamlines workflows and reduces errors. Strategic collaborations among market players are also accelerating global adoption.
2024 Market Size: USD 22.51 billion
2034 Forecast: USD 63.94 billion
CAGR (2025-2034): 11.02%
North America Share (2024): 41%
Fastest-Growing Region: Asia Pacific
Top Segment by Product: Instruments (40% share in 2024)
Fastest Growing Segment: Consumables
Let’s explore the key companies driving innovation and shaping the competitive landscape of the cell cycle analysis market.
About: BD Biosciences, a division of Becton, Dickinson and Company, is a leader in flow cytometry and cell analysis solutions.
Products: Flow cytometers, reagents, and software for cell cycle analysis and immunology research.
Market Cap: Approx. USD 70 billion.
About: A global giant in life sciences, Thermo Fisher drives innovation in laboratory technologies.
Products: Attune NxT Flow Cytometers, reagents, and cloud-based analysis platforms.
Market Cap: Approx. USD 230 billion.
About: Operates under the MilliporeSigma brand in the U.S. and Canada, focusing on life science tools and solutions.
Products: Cell cycle reagents, flow cytometry kits, and analytics platforms.
Market Cap: Approx. USD 25 billion.
About: Agilent specializes in analytical instrumentation and life science tools.
Products: Flow cytometers, cellular analysis software, and reagents.
Market Cap: Approx. USD 30 billion.
About: A pioneer in developing and manufacturing life science research and clinical diagnostics products.
Products: Flow cytometers, reagents, and software for cell cycle studies.
Market Cap: Approx. USD 14 billion.
About: Danaher owns Beckman Coulter, renowned for advanced flow cytometry solutions.
Products: CytoFLEX systems, Kaluza analysis software, and reagents.
Market Cap: Approx. USD 190 billion.
About: A major player in medical technologies and life sciences solutions.
Products: Cytiva flow cytometry systems and cell analysis tools.
Market Cap: Approx. USD 35 billion.
About: Focused on diagnostics and life science research, PerkinElmer provides high-performance tools.
Products: Cellular imaging systems, reagents, and analytics platforms.
Market Cap: Approx. USD 15 billion.
About: Privately held leader in providing reagents and kits for cell biology research.
Products: Cell proliferation and viability kits, reporter assays for cell cycle analysis.
Market Cap: Estimated USD 5 billion (private).
About: A subsidiary of Enzo Biochem, offering innovative tools for genomics and proteomics.
Products: Cell cycle and apoptosis assay kits, detection reagents.
Market Cap: Approx. USD 200 million.
About: Based in Japan, Sysmex develops advanced diagnostic systems and reagents.
Products: Flow cytometers and hematology analyzers.
Market Cap: Approx. USD 16 billion.
About: A global provider of products and services for biomedical research and clinical applications.
Products: Flow cytometry systems, MACSQuant analyzers, and cell separation kits.
Market Cap: Estimated USD 2 billion (private).
About: A U.K.-based supplier of protein research tools and reagents.
Products: Cell cycle and apoptosis assay kits, antibodies.
Market Cap: Approx. USD 4 billion.
About: Acquired by DiaSorin, Luminex offers multiplexing solutions for biological analysis.
Products: Flow-based analyzers, detection reagents, and xMAP technology.
Market Cap: Approx. USD 1.7 billion.
Rising Disease Burden: Increased prevalence of cancer and chronic diseases drives demand for advanced cell analysis tools.
Technological Advancements: Integration of AI and machine learning enhances accuracy and reduces manual errors.
Research and Development Boost: Growing investments in biotech and pharmaceutical R&D propel market growth.
Regional Expansion: Emerging markets in Asia Pacific offer lucrative growth opportunities due to improving healthcare infrastructure.
Collaborations and Partnerships: Strategic alliances among key players are driving innovation and global reach.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Q1. What is the projected market size of the cell cycle analysis market by 2034?
A1. The market is expected to reach approximately USD 63.94 billion by 2034.
Q2. Which region dominates the cell cycle analysis market?
A2. North America held a 41% share in 2024 and continues to dominate the market.
Q3. Which product segment is growing the fastest?
A3. The consumables segment is projected to grow at the fastest pace during the forecast period.
Q4. How is AI transforming cell cycle analysis?
A4. AI integration improves workflow efficiency, enhances data accuracy, and reduces human errors.
Q5. Who are the top three players in the global market?
A5. Thermo Fisher Scientific, BD Biosciences, and Danaher Corporation (Beckman Coulter) are among the top three market leaders.
Source : https://www.towardshealthcare.com/insights/cell-cycle-analysis-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5853
The global Quantum Computing in Healthcare market grew from USD 121.6 million in 2024 to USD 167.71 million in 2025… Read More
The global blockchain in clinical trials market is transitioning from pilots to scaled deployments—projected to reach the high-hundreds of millions… Read More
The global endocrine testing market was valued at USD 2.99 billion in 2024, grew to USD 3.24 billion in 2025,… Read More
The global behavioral health market reached US$173.35 billion in 2024, grew to US$185.03 billion in 2025, and is forecast to… Read More
The global gene-editing therapeutics market is set for strong growth (2025–2034), led by CRISPR (48%), ex-vivo therapies (53%), and North… Read More
The global e-commerce in healthcare market is experiencing rapid expansion (projected to reach several hundred million dollars by the end… Read More